TGTX Historical Balance Sheet

TGTX Stock

USD 31.67 1.17 3.56%

Trend analysis of TG Therapeutics balance sheet accounts such as Property Plant And Equipment Net of 8.6 M, Net Debt of 18.8 M, Cash of 59.3 M or Non Current Assets Total of 7.5 M provides information on TG Therapeutics' total assets, liabilities, and equity, which is the actual value of TG Therapeutics to its prevalent stockholders. By breaking down trends over time using TG Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining TG Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether TG Therapeutics is a good buy for the upcoming year.

TG Therapeutics Inventory

41.81 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

About TGTX Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of TG Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. TG Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of TG Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which TGTX currently owns. An asset can also be divided into two categories, current and non-current.

TG Therapeutics Balance Sheet Chart

At this time, TG Therapeutics' Total Liabilities is fairly stable compared to the past year. Property Plant And Equipment Gross is likely to rise to about 10 M in 2024, despite the fact that Retained Earnings are likely to grow to (1.4 B).

Total Assets Other Current Liab Total Current Liabilities Liabilities And Stockholders Equity Long Term Debt Long Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of TG Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in TG Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on TG Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of TG Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Liabilities And Stockholders Equity

The total of all liabilities and equity in the company, which should equal the company's total assets according to the accounting equation.

Long Term Debt

Long-term debt is a debt that TG Therapeutics has held for over one year. Long-term debt appears on TG Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on TG Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Long Term Investments

Long Term Investments is an item on the asset side of TG Therapeutics balance sheet that represents investments TG Therapeutics intends to hold for over a year. TG Therapeutics long term investments may include different instruments such as stocks, bonds, real estate and cash.

Most accounts from TG Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into TG Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TG Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.At this time, TG Therapeutics' Total Liabilities is fairly stable compared to the past year. Property Plant And Equipment Gross is likely to rise to about 10 M in 2024, despite the fact that Retained Earnings are likely to grow to (1.4 B).

	2021	2022	2023	2024 (projected)
Other Current Liabilities	61.5M	8.0M	13.5M	14.2M
Total Assets	379.6M	193.6M	329.6M	346.1M

Other Current Liab Total Assets

TG Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Other Current Assets	Accounts Payable	Common Stock Total Equity	Common Stock	Other Assets	Property Plant Equipment	Short Long Term Debt Total	Short Term Investments
Total Assets		0.72	0.82	-0.03	0.8	-0.74	-0.75	0.88	0.47	0.98	0.79	0.82	0.69	0.82	1.0	-0.23	0.39	0.57	0.77	0.52	-0.11	-0.08	0.41	0.76	0.68	0.59
Other Current Liab	0.72		0.6	-0.44	0.66	-0.58	-0.62	0.7	0.79	0.73	0.61	0.66	0.5	0.65	0.69	-0.15	0.13	0.49	0.86	0.02	0.01	0.02	0.13	0.78	0.56	0.19
Total Current Liabilities	0.82	0.6		-0.32	0.96	-0.56	-0.8	0.71	0.47	0.8	0.84	0.68	0.73	0.96	0.82	-0.28	0.28	0.61	0.64	0.7	-0.13	-0.11	0.3	0.8	0.68	0.53
Total Stockholder Equity	-0.03	-0.44	-0.32		-0.48	-0.07	0.44	-0.06	-0.69	-0.06	-0.34	-0.26	-0.29	-0.44	0.02	0.08	0.22	-0.37	-0.41	-0.02	-0.06	-0.05	0.23	-0.34	-0.36	0.09
Property Plant And Equipment Net	0.8	0.66	0.96	-0.48		-0.48	-0.87	0.67	0.56	0.78	0.87	0.75	0.74	1.0	0.79	-0.25	0.3	0.71	0.74	0.64	-0.05	-0.03	0.32	0.82	0.78	0.55
Net Debt	-0.74	-0.58	-0.56	-0.07	-0.48		0.21	-0.96	-0.35	-0.85	-0.27	-0.33	-0.16	-0.44	-0.75	0.13	0.27	0.09	-0.31	-0.13	0.03	0.05	0.25	-0.5	-0.06	0.05
Retained Earnings	-0.75	-0.62	-0.8	0.44	-0.87	0.21		-0.46	-0.54	-0.66	-0.98	-0.94	-0.85	-0.9	-0.74	0.26	-0.6	-0.92	-0.88	-0.7	0.09	0.05	-0.6	-0.77	-0.95	-0.79
Cash	0.88	0.7	0.71	-0.06	0.67	-0.96	-0.46		0.47	0.96	0.49	0.55	0.37	0.64	0.88	-0.17	-0.07	0.18	0.53	0.27	-0.03	-0.04	-0.05	0.65	0.32	0.16
Non Current Assets Total	0.47	0.79	0.47	-0.69	0.56	-0.35	-0.54	0.47		0.5	0.52	0.51	0.53	0.53	0.42	-0.12	-0.06	0.41	0.68	-0.01	-0.08	-0.09	-0.07	0.52	0.46	0.06
Cash And Short Term Investments	0.98	0.73	0.8	-0.06	0.78	-0.85	-0.66	0.96	0.5		0.7	0.74	0.59	0.77	0.98	-0.22	0.2	0.43	0.69	0.44	-0.09	-0.07	0.22	0.73	0.55	0.44
Common Stock Shares Outstanding	0.79	0.61	0.84	-0.34	0.87	-0.27	-0.98	0.49	0.52	0.7		0.92	0.91	0.9	0.78	-0.35	0.6	0.89	0.84	0.75	-0.24	-0.2	0.61	0.78	0.9	0.82
Other Stockholder Equity	0.82	0.66	0.68	-0.26	0.75	-0.33	-0.94	0.55	0.51	0.74	0.92		0.78	0.79	0.81	-0.24	0.6	0.85	0.91	0.62	-0.09	-0.05	0.61	0.76	0.88	0.78
Total Liab	0.69	0.5	0.73	-0.29	0.74	-0.16	-0.85	0.37	0.53	0.59	0.91	0.78		0.78	0.67	-0.38	0.6	0.8	0.73	0.64	-0.36	-0.32	0.61	0.61	0.81	0.79
Property Plant And Equipment Gross	0.82	0.65	0.96	-0.44	1.0	-0.44	-0.9	0.64	0.53	0.77	0.9	0.79	0.78		0.8	-0.25	0.39	0.76	0.77	0.67	-0.06	-0.03	0.4	0.82	0.83	0.62
Total Current Assets	1.0	0.69	0.82	0.02	0.79	-0.75	-0.74	0.88	0.42	0.98	0.78	0.81	0.67	0.8		-0.23	0.4	0.56	0.74	0.54	-0.1	-0.07	0.42	0.74	0.67	0.61
Non Currrent Assets Other	-0.23	-0.15	-0.28	0.08	-0.25	0.13	0.26	-0.17	-0.12	-0.22	-0.35	-0.24	-0.38	-0.25	-0.23		-0.1	-0.17	-0.18	-0.29	0.36	0.36	-0.11	-0.34	-0.16	-0.23
Net Receivables	0.39	0.13	0.28	0.22	0.3	0.27	-0.6	-0.07	-0.06	0.2	0.6	0.6	0.6	0.39	0.4	-0.1		0.8	0.55	0.48	-0.08	0.0	1.0	0.29	0.76	0.91
Non Current Liabilities Total	0.57	0.49	0.61	-0.37	0.71	0.09	-0.92	0.18	0.41	0.43	0.89	0.85	0.8	0.76	0.56	-0.17	0.8		0.84	0.59	-0.06	-0.01	0.8	0.6	0.98	0.85
Other Current Assets	0.77	0.86	0.64	-0.41	0.74	-0.31	-0.88	0.53	0.68	0.69	0.84	0.91	0.73	0.77	0.74	-0.18	0.55	0.84		0.33	-0.01	0.03	0.55	0.78	0.88	0.62
Accounts Payable	0.52	0.02	0.7	-0.02	0.64	-0.13	-0.7	0.27	-0.01	0.44	0.75	0.62	0.64	0.67	0.54	-0.29	0.48	0.59	0.33		-0.22	-0.19	0.5	0.49	0.58	0.76
Common Stock Total Equity	-0.11	0.01	-0.13	-0.06	-0.05	0.03	0.09	-0.03	-0.08	-0.09	-0.24	-0.09	-0.36	-0.06	-0.1	0.36	-0.08	-0.06	-0.01	-0.22		1.0	-0.08	0.1	-0.03	-0.18
Common Stock	-0.08	0.02	-0.11	-0.05	-0.03	0.05	0.05	-0.04	-0.09	-0.07	-0.2	-0.05	-0.32	-0.03	-0.07	0.36	0.0	-0.01	0.03	-0.19	1.0		-0.01	0.12	0.03	-0.11
Other Assets	0.41	0.13	0.3	0.23	0.32	0.25	-0.6	-0.05	-0.07	0.22	0.61	0.61	0.61	0.4	0.42	-0.11	1.0	0.8	0.55	0.5	-0.08	-0.01		0.29	0.76	0.92
Property Plant Equipment	0.76	0.78	0.8	-0.34	0.82	-0.5	-0.77	0.65	0.52	0.73	0.78	0.76	0.61	0.82	0.74	-0.34	0.29	0.6	0.78	0.49	0.1	0.12	0.29		0.65	0.46
Short Long Term Debt Total	0.68	0.56	0.68	-0.36	0.78	-0.06	-0.95	0.32	0.46	0.55	0.9	0.88	0.81	0.83	0.67	-0.16	0.76	0.98	0.88	0.58	-0.03	0.03	0.76	0.65		0.84
Short Term Investments	0.59	0.19	0.53	0.09	0.55	0.05	-0.79	0.16	0.06	0.44	0.82	0.78	0.79	0.62	0.61	-0.23	0.91	0.85	0.62	0.76	-0.18	-0.11	0.92	0.46	0.84

Click cells to compare fundamentals

TG Therapeutics Account Relationship Matchups

TG Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	163.0M	625.6M	379.6M	193.6M	329.6M	346.1M
Other Current Liab	5.4M	26.7M	61.5M	8.0M	13.5M	14.2M
Total Current Liabilities	84.4M	87.6M	65.4M	53.2M	53.7M	56.4M
Total Stockholder Equity	(701.2M)	519.4M	(1.3B)	(1.5B)	160.5M	168.5M
Property Plant And Equipment Net	11.8M	11.8M	11.1M	10.8M	8.1M	8.6M
Net Debt	(71.8M)	(511.5M)	(219.8M)	(19.2M)	17.9M	18.8M
Retained Earnings	(701.2M)	(980.6M)	(1.3B)	(1.5B)	(1.5B)	(1.4B)
Cash	112.6M	553.4M	298.9M	102.3M	92.9M	59.3M
Non Current Assets Total	13.9M	13.9M	48.7M	25.3M	11.6M	7.5M
Cash And Short Term Investments	140.4M	605.4M	350.3M	174.1M	217.5M	228.4M
Common Stock Shares Outstanding	88.4M	115.3M	132.2M	135.4M	148.5M	155.9M
Liabilities And Stockholders Equity	(576.8M)	625.6M	(1.2B)	(1.4B)	329.6M	346.1M
Other Stockholder Equity	(109K)	1.5B	1.6B	1.6B	1.7B	1.8B
Total Liab	124.4M	106.3M	142.5M	135.0M	169.1M	177.5M
Property Plant And Equipment Gross	11.8M	11.8M	11.1M	10.8M	9.6M	10.0M
Total Current Assets	149.2M	611.7M	331.0M	168.3M	317.9M	333.8M
Non Currrent Assets Other	1.3M	1.3M	1.3M	1.3M	1.4M	1.3M
Net Receivables	108.5K	95K	0.0	1.4M	51.1M	53.6M
Non Current Liabilities Total	40.0M	18.7M	77.1M	81.8M	115.4M	121.1M
Other Current Assets	611K	6.3M	14.8M	6.6M	9.5M	10.0M
Accounts Payable	30.0M	37.0M	(457K)	42.0M	38.5M	40.4M
Common Stock Total Equity	109K	141K	143K	146K	131.4K	74.7K
Common Stock	109K	141K	143K	146K	151K	105.2K
Other Assets	3.4M	13.1M	3.1M	2.9M	329.6M	346.1M
Property Plant Equipment	282K	481K	600K	307K	353.1K	370.7K
Short Long Term Debt Total	40.8M	42.0M	79.0M	83.1M	110.8M	116.3M
Short Term Investments	27.8M	52.0M	15.9M	59.4M	124.6M	130.8M
Other Liab	762K	610K	457K	305K	274.5K	260.8K
Short Term Debt	1.6M	23.8M	3.8M	3.2M	1.4M	2.8M
Net Tangible Assets	37.8M	518.6M	310.7M	57.8M	66.5M	118.5M
Retained Earnings Total Equity	(701.2M)	(980.6M)	(1.3B)	(1.5B)	(1.4B)	(1.3B)
Capital Surpluse	740.0M	1.5B	1.6B	1.6B	1.8B	1.9B
Deferred Long Term Liab	762K	610K	457K	305K	274.5K	260.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

TGTX Historical Balance Sheet

TG Therapeutics Inventory

41.81 Million

About TGTX Balance Sheet Analysis

TG Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Liabilities And Stockholders Equity

Long Term Debt

Long Term Investments

TG Therapeutics balance sheet Correlations

TG Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

TG Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for TGTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Other Assets	+ 1.0	Net Receivables
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Cash And Short Term Investments

Common Stock Shares Outstanding	- 0.98	Retained Earnings
Cash	- 0.96	Net Debt
Short Long Term Debt Total	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Non Current Liabilities Total	- 0.92	Retained Earnings
Property Plant And Equipment Gross	- 0.9	Retained Earnings